Viewing Study NCT01645332


Ignite Creation Date: 2025-12-24 @ 9:54 PM
Ignite Modification Date: 2025-12-25 @ 7:32 PM
Study NCT ID: NCT01645332
Status: COMPLETED
Last Update Posted: 2014-10-08
First Post: 2012-07-18
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Efficacy and Safety of DLBS3233 in Subjects With New Onset of Type 2 Diabetes Mellitus
Sponsor: Dexa Medica Group
Organization:

Study Overview

Official Title: Role of DLBS3233 in the Treatment of Subjects With New Onset of Type 2 Diabetes Mellitus
Status: COMPLETED
Status Verified Date: 2014-10
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This is a 2-arm, double-blind, parallel, randomized, placebo-controlled clinical study, with 12 weeks of therapy to evaluate the efficacy and safety of DLBS3233 in improving metabolic control in newly diagnosed type-2-diabetic patients, as measured by A1c level, fasting and 2-hours post-prandial plasma glucose, fasting insulin level, HOMA-IR, HOMA-B, adiponectin level, lipid profile, and body weight.
Detailed Description: There will be two groups of treatment in this study who will receive DLBS3233 or placebo of DLBS3233 (with lifestyle modification) for 12 weeks of therapy.

Clinical and physical examination to evaluate the efficacy and safety as well as measurement of fasting and 2-hour post-prandial plasma glucose level will be performed at baseline and every 6-weeks-interval. Other clinical and laboratory examinations will be performed at baseline and at the end of study.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: